Evidence map›Paper›PMID 42339818›Full record

Trial reportAnnals of medicine2026

Impact of oliceridine versus sufentanil on postoperative nausea and vomiting in patients undergoing thyroid surgery: a prospective, double-blind, randomized controlled trial.

Feng Liu, Wang Shen, Dan Su, Zhaoming Guan, Yi Zhang, Siyu Li, Qisong Yuan, Yupeng Zhao, Jixiong Sun, Hongwei Fang and 1 more

Abstract readRandomized Controlled TrialComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Annals of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Feng LiuDepartment of Anesthesiology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Wang ShenDepartment of Anesthesiology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.ORCID 0000-0002-2440-9631
Dan SuDepartment of Anesthesiology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Zhaoming GuanDepartment of Anesthesiology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Yi ZhangDepartment of Anesthesiology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Siyu LiDepartment of Anesthesiology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Qisong YuanDepartment of Anesthesiology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Yupeng ZhaoDepartment of Anesthesiology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Jixiong SunDepartment of Anesthesiology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Hongwei FangDepartment of Pain Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.ORCID 0000-0001-5577-4044
Longqiu YangDepartment of Anesthesiology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.ORCID 0009-0000-5641-2360

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePostoperative nausea and vomiting (PONV) is a common complication following thyroid surgery, often exacerbated by opioid use. Oliceridine, a novel G protein-biased μ-opioid receptor agonist, may reduce opioid-related adverse events. This study aimed to compare the impact of oliceridine versus sufentanil on the incidence and severity of PONV in patients undergoing thyroid surgery. PATIENTS AND

methodsIn this prospective, double-blind, randomised controlled trial conducted between May 2025 and February 2026, 232 patients scheduled for thyroid surgery were randomly assigned to receive either oliceridine or sufentanil for intraoperative analgesia. The primary outcome was the incidence of PONV during the first 48 h postoperatively. Secondary outcomes included PONV severity, need for rescue anti-emetics, postoperative pain scores, recovery quality, and other adverse events.

resultsThe incidence of PONV within 48 h postoperatively was significantly lower in the oliceridine group [13/107 (12%)] compared with the sufentanil group [31/110 (28%)] (OR = 0.35, 95% CI: 0.17-0.72,

conclusionFor young ASA I-II patients undergoing thyroid surgery, oliceridine yields adequate postoperative analgesia and lower PONV rates versus sufentanil. Additional trials involving high-intensity surgical procedures are needed to confirm consistent equivalence.

Indexed as

Postoperative Nausea and VomitingSufentanilThyroidectomyThyroid GlandAdultAnalgesics, OpioidAntiemeticsDouble-Blind MethodFemaleHumansIncidenceMaleMiddle AgedPostoperative PainProspective StudiesSpiro Compounds((3-methoxythiophen-2-yl)methyl)((2-(9-(pyridin-2-yl)-6-oxaspiro(4.5)decan-9-yl)ethyl))amineAnalgesics, OpioidAntiemeticsSpiro CompoundsSufentanilThiophenesOliceridineopioid-related adverse eventspostoperative nausea and vomitingsufentanilthyroid surgery

Identifiers

PMID42339818
PMCPMC13295068

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.